List of Kynamro drug patents

Kynamro is owned by Kastle Theraps Llc.

Kynamro contains Mipomersen Sodium.

Kynamro has a total of 3 drug patents out of which 0 drug patents have expired.

Kynamro was authorised for market use on 29 January, 2013.

Kynamro is available in solution;subcutaneous dosage forms.

The generics of Kynamro are possible to be released after 29 January, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7015315 KASTLE THERAPS LLC Gapped oligonucleotides
Mar, 2023

(a month from now)

US7101993 KASTLE THERAPS LLC Oligonucleotides containing 2′-O-modified purines
Sep, 2023

(6 months from now)

US7511131 KASTLE THERAPS LLC Antisense modulation of apolipoprotein B expression
Jan, 2027

(3 years from now)

Drugs and Companies using MIPOMERSEN SODIUM ingredient

Market Authorisation Date: 29 January, 2013

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic